FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 07:32:05 2024-06-04 EDT | ||
| 0.54 EUR | +1.89% |
|
| Current month | +12.77% | ||
| 1 month | -32.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 0.54 | +1.89% |
| 24-06-03 | 0.53 | +12.77% |
| 24-05-31 | 0.47 | +9.30% |
| 24-05-30 | 0.43 | -2.27% |
| 24-05-29 | 0.44 | -2.22% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 07:32 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3R6U |
| ISIN | DE000SW3R6U3 |
| Date issued | 2023-09-21 |
| Strike | 58.64 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.78 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.01 € |
| Spread % | 1.82% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.77
USD
Average target price
53.19
USD
Spread / Average Target
+27.35%
- Stock Market
- Certificates
- Certificat
